Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 16/20 | 0.78 |
| ▸ | PTGDR | Q13258 | 7/20 | 0.78 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.71 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4878416 | 0.84 | PTGDR2 (0.74) | PTGDR2PTGDRPTGER2SMN1; SMN2ALDH1A1 | |
| SCHEMBL4888054 | 0.83 | PTGDR2 (1.00) | PTGDR2PTGDRPTGER2TDP1 | |
| SCHEMBL4875122 | 0.83 | PTGDR2 (1.00) | PTGDR2PTGDRPTGER2TDP1 | |
| SCHEMBL4876391 | 0.83 | PTGDR2 (0.59) | PTGDR2PTGDRPTGER2 | |
| SCHEMBL4882978 | 0.82 | PTGDR2 (0.73) | PTGDR2PTGDRPTGER2HPGDALDH1A1 | |
| SCHEMBL4879219 | 0.82 | PTGDR2 (1.00) | PTGDR2PTGDRPTGER2TDP1 | |
| SCHEMBL4879185 | 0.80 | PTGDR2 (0.74) | PTGDR2PTGDRPTGER2LMNAHPGD | |
| SCHEMBL24737341 | 0.79 | PTGDR (0.49) | PTGDR2PTGDRPTGER2NPC1HPGD | |
| SCHEMBL30997763 | 0.79 | PTGDR (0.49) | PTGDR2PTGDRPTGER2NPC1HPGD | |
| SCHEMBL29302269 | 0.79 | PTGDR (0.49) | PTGDR2PTGDRPTGER2NPC1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269335-A1 | 2-(4-Chloro-2-cyclohexylphenoxy)propionic acid; (4-Bromo-2-cyclohexylphenoxy)propionic acid ethyl ester; ethyl-2-bromopropionate is reacted with 4-chloro-2-cyclohexylphenol in presence of cesium carbonate and N,N-dimethylfomamide; antiallergenic and antiinflammatory agent | NOVARTIS AG (CH) | 2008-10-30 | — | — | US | disclosed |
| EP-1756032-A1 | CRTH2 RECEPTOR ANTAGONISTS | Novartis AG (CH) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005105727-A1 | CRTH2 RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269335-A1 | 2-(4-Chloro-2-cyclohexylphenoxy)propionic acid; (4-Bromo-2-cyclohexylphenoxy)propionic acid ethyl ester; ethyl-2-bromopropionate is reacted with 4-chloro-2-cyclohexylphenol in presence of cesium carbonate and N,N-dimethylfomamide; antiallergenic and antiinflammatory agent | EPX, NR3C2, FPR2 | PTGDR2 245/4885PTGDR 151/4885PTGER2 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.